AIM
IOVA icon

Assured Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Assured Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-49
Closed – – 428
2019
Q1 		$0 Buy
+49
New +$476 ﹤0.01% 1234
2018
Q4 		– Sell
-712
Closed -$8K – 1222
2018
Q3 		$8K Sell
712
-28,899
-98% -$410K ﹤0.01% 1134
2018
Q2 		$379K Buy
+29,611
New +$433K 0.01% 889

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Assured Investment Management's IOVA Position: Q2 2019 in Review

Assured Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 49 shares.

Assured Investment Management first reported a position in IOVA in Q2 2018 and held it in 3 quarters. The position peaked at $379K in Q2 2018. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

  • Assured Investment Management reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 49 Iovance Biotherapeutics shares in Q2 2019.
  • Assured Investment Management first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 3 quarters.
  • Assured Investment Management's Iovance Biotherapeutics position peaked at $379K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.